Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal

 
• By Alaric DeArment

The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.

Digital illustration of Cancer cell in colour background
Agenus said it would withdraw the BLA for its PD-1 inhibitor, balstilimab, in 2L cervical cancer • Source: Shutterstock

More from Immuno-oncology

More from Anticancer